CL2019003257A1 - Derivados de indol n–sustituidos. - Google Patents

Derivados de indol n–sustituidos.

Info

Publication number
CL2019003257A1
CL2019003257A1 CL2019003257A CL2019003257A CL2019003257A1 CL 2019003257 A1 CL2019003257 A1 CL 2019003257A1 CL 2019003257 A CL2019003257 A CL 2019003257A CL 2019003257 A CL2019003257 A CL 2019003257A CL 2019003257 A1 CL2019003257 A1 CL 2019003257A1
Authority
CL
Chile
Prior art keywords
indole derivatives
substituted indole
formula
derivatives
prostaglandin
Prior art date
Application number
CL2019003257A
Other languages
English (en)
Inventor
Heinz Fretz
Isabelle Lyothier
Julien Pothier
Sylvia Richard-Bildstein
Thierry Sifferlen
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CL2019003257A1 publication Critical patent/CL2019003257A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA CON DERIVADOS DE LA FÓRMULA (I), DONDE R1, Y R2 SON COMO SE LOS DESCRIBE EN LA MEMORIA, CON SU PREPARACIÓN, CON SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, Y CON SU USO COMO PRODUCTOS FARMACÉUTICOS, CON COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN UNO O MÁS COMPUESTOS DE LA FÓRMULA (I), Y ESPECIALMENTE CON SU USO COMO MODULADORES DEL RECEPTOR EP2 DE LA PROSTAGLANDINA 2.
CL2019003257A 2017-05-18 2019-11-14 Derivados de indol n–sustituidos. CL2019003257A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2017062008 2017-05-18

Publications (1)

Publication Number Publication Date
CL2019003257A1 true CL2019003257A1 (es) 2020-03-27

Family

ID=62186481

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003257A CL2019003257A1 (es) 2017-05-18 2019-11-14 Derivados de indol n–sustituidos.

Country Status (32)

Country Link
US (2) US20200069686A1 (es)
EP (1) EP3625224B1 (es)
JP (1) JP7065117B2 (es)
KR (1) KR102650756B1 (es)
CN (1) CN110621666A (es)
AR (1) AR111806A1 (es)
AU (1) AU2018269667B2 (es)
BR (1) BR112019024114A2 (es)
CA (1) CA3063637A1 (es)
CL (1) CL2019003257A1 (es)
CO (1) CO2019010804A2 (es)
CR (1) CR20190567A (es)
CY (1) CY1124528T1 (es)
DK (1) DK3625224T3 (es)
EA (1) EA039630B1 (es)
ES (1) ES2894124T3 (es)
HR (1) HRP20211532T1 (es)
HU (1) HUE056406T2 (es)
IL (1) IL270616B (es)
LT (1) LT3625224T (es)
MA (1) MA49127B1 (es)
MX (1) MX2019013639A (es)
PE (1) PE20191787A1 (es)
PH (1) PH12019502562A1 (es)
PL (1) PL3625224T3 (es)
PT (1) PT3625224T (es)
RS (1) RS62441B1 (es)
SG (1) SG11201908660RA (es)
SI (1) SI3625224T1 (es)
TW (1) TWI768043B (es)
UA (1) UA124748C2 (es)
WO (1) WO2018210995A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
DK3625228T3 (da) 2017-05-18 2021-10-11 Idorsia Pharmaceuticals Ltd Pyrimidinderivater som pge2-receptormodulatorer
CA3063788A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
WO2018210987A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as pge2 receptor modulators
AR111941A1 (es) 2017-05-18 2019-09-04 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
WO2021060281A1 (ja) * 2019-09-24 2021-04-01 Ａｇｃ株式会社 プロスタグランジンｅ２レセプターｅｐ２／ｅｐ４デュアルアンタゴニスト
CN115697317A (zh) * 2020-04-08 2023-02-03 株式会社AskAt Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用
JPWO2022102731A1 (es) 2020-11-13 2022-05-19

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE395058T1 (de) 2000-03-24 2008-05-15 Asterand Uk Ltd Verwendung von prostanoid-ep4-rezeptor- antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
AU2003216581A1 (en) 2002-04-12 2003-10-27 Pfizer Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
WO2003086390A1 (en) 2002-04-12 2003-10-23 Pfizer Japan Inc. Imidazole compounds as anti-inflammatory and analgesic agents
CN1662551A (zh) 2002-05-23 2005-08-31 瑟瑞技术公司 前列腺素e2受体亚型ep4的拮抗肽
ES2308139T3 (es) 2003-01-29 2008-12-01 Asterand Uk Limited Antagonista de receptos ep4.
CN1871240B (zh) * 2003-08-26 2012-11-07 帝人制药株式会社 吡咯并嘧啶酮衍生物
WO2005021508A1 (en) 2003-09-03 2005-03-10 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
EP1756043B1 (en) 2004-05-04 2009-07-01 RaQualia Pharma Inc Ortho substituted aryl or heteroaryl amide compounds
CA2565813C (en) 2004-05-04 2010-10-26 Pfizer Inc. Substituted methyl aryl or heteroaryl amide compounds
GT200500284A (es) 2004-10-15 2006-03-27 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
AU2006246930C1 (en) 2005-05-19 2012-01-19 Merck Canada Inc. Quinoline derivatives as EP4 antagonists
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
EP2013169B1 (en) 2006-04-24 2012-08-22 Merck Canada Inc. Indole amide derivatives as ep4 receptor antagonists
JP5183628B2 (ja) 2006-06-12 2013-04-17 メルク カナダ インコーポレイテッド Ｅｐ４受容体リガンドとしてのインドリンアミド誘導体
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
JP4960450B2 (ja) 2006-07-14 2012-06-27 ノバルティス アーゲー Ａｌｋ−５阻害剤としてのピリミジン誘導体
CA2660133C (en) 2006-08-11 2015-10-27 Merck Frosst Canada Ltd. Thiophenecarboxamide derivatives as ep4 receptor ligands
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
EP2114877B1 (en) 2007-02-26 2012-12-26 Merck Canada Inc. Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists
JP2010522218A (ja) 2007-03-26 2010-07-01 メルク フロスト カナダ リミテツド Ｅｐ４受容体アンタゴニストとしてのナフタレン及びキノリンスルホニル尿素誘導体
MX2009010297A (es) 2007-03-26 2009-10-12 Astellas Pharma Inc Derivado de ornitina.
EP2014657A1 (de) * 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
WO2009005076A1 (ja) 2007-07-03 2009-01-08 Astellas Pharma Inc. アミド化合物
PT2565191E (pt) 2008-05-14 2014-12-04 Astellas Pharma Inc Derivados do ácido 4-(indol-7- ilcarbonilaminometil)ciclo-hexanocarboxílico como antagonistas de receptores ep4, úteis no tratamento de insuficiência renal crónica ou de nefropatia diabética
JP5536773B2 (ja) 2008-08-14 2014-07-02 ベータ・ファーマ・カナダ・インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのヘテロ環式アミド誘導体
US9029414B2 (en) 2008-09-19 2015-05-12 Biotechnology Research Corporation Triterpenoid compounds and methods of use thereof
WO2010034110A1 (en) 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
WO2011144742A1 (en) 2010-05-21 2011-11-24 Chemilia Ab Novel pyrimidine derivatives
AU2011305872B2 (en) 2010-09-21 2015-03-26 Eisai R&D Management Co., Ltd. Pharmaceutical composition
EP2623594B9 (en) 2010-09-29 2015-07-22 NB Health Laboratory Co. Ltd. Antibody against human prostaglandin e2 receptor ep4
ES2545110T3 (es) 2010-12-10 2015-09-08 Rottapharm Biotech S.R.L. Derivados de piridinamida como antagonistas del receptor EP4
WO2012103071A2 (en) 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Compounds and compositions
AU2012230229A1 (en) * 2011-03-24 2013-10-10 Noviga Research Ab Novel pyrimidine derivatives
PL2729445T3 (pl) 2011-07-04 2016-04-29 Rottapharm Biotech Srl Cykliczne pochodne aminowe jako antagoniści receptora EP4
EP2554662A1 (en) 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
SG10201704095UA (en) 2012-04-24 2017-06-29 Vertex Pharma Dna-pk inhibitors
JO3296B1 (ar) 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين
TWI572597B (zh) 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基－苯甲酸化合物
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2765128A1 (en) 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
TW201443004A (zh) 2013-02-15 2014-11-16 Lilly Co Eli 苯氧基乙氧基化合物
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
EP3009426B1 (en) 2013-06-12 2018-05-02 Kaken Pharmaceutical Co., Ltd. 4-alkynyl imidazole derivative and medicine comprising same as active ingredient
BR112016004194A8 (pt) 2013-09-04 2020-02-11 Bristol Myers Squibb Co compostos úteis como imunomoduladores
SG11201601682RA (en) 2013-09-06 2016-04-28 Aurigene Discovery Tech Ltd 1,2,4-oxadiazole derivatives as immunomodulators
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
TR201807411T4 (tr) 2013-10-17 2018-06-21 Vertex Pharma DNA-PK inhibitörleri.
AU2014366361B2 (en) 2013-12-17 2017-04-20 Eli Lilly And Company Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators
AU2014366371B2 (en) 2013-12-17 2017-02-16 Eli Lilly And Company Dimethylbenzoic acid compounds
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
AU2015264102C1 (en) 2014-05-23 2020-10-08 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of cancer
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
WO2016054807A1 (en) 2014-10-10 2016-04-14 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
SG11201705628UA (en) 2015-01-09 2017-08-30 Ono Pharmaceutical Co Tricyclic spiro compound
CA2993312A1 (en) 2015-07-23 2017-01-26 Takeda Pharmaceutical Company Limited 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
BR112018007664B1 (pt) 2015-10-16 2023-12-19 Eisai R&D Management Co., Ltd Compostos antagonistas de ep4, composição compreendendo o composto e uso dos mesmos para tratar câncer

Also Published As

Publication number Publication date
MA49127B1 (fr) 2022-05-31
CY1124528T1 (el) 2022-07-22
TWI768043B (zh) 2022-06-21
EA201992679A1 (ru) 2020-05-06
DK3625224T3 (da) 2021-11-08
WO2018210995A1 (en) 2018-11-22
PE20191787A1 (es) 2019-12-24
JP7065117B2 (ja) 2022-05-11
CA3063637A1 (en) 2018-11-22
LT3625224T (lt) 2021-10-25
RS62441B1 (sr) 2021-11-30
ES2894124T3 (es) 2022-02-11
SI3625224T1 (sl) 2021-11-30
HRP20211532T1 (hr) 2022-01-07
EP3625224A1 (en) 2020-03-25
MX2019013639A (es) 2020-01-21
HUE056406T2 (hu) 2022-02-28
JP2020520359A (ja) 2020-07-09
KR20200006589A (ko) 2020-01-20
CN110621666A (zh) 2019-12-27
PL3625224T3 (pl) 2022-01-10
US20200069686A1 (en) 2020-03-05
EA039630B1 (ru) 2022-02-18
PH12019502562A1 (en) 2020-07-20
TW201900637A (zh) 2019-01-01
AU2018269667A1 (en) 2019-10-24
IL270616B (en) 2022-01-01
CR20190567A (es) 2020-02-10
CO2019010804A2 (es) 2019-10-09
US20230165859A1 (en) 2023-06-01
PT3625224T (pt) 2021-10-06
AU2018269667B2 (en) 2022-02-03
BR112019024114A2 (pt) 2020-06-02
EP3625224B1 (en) 2021-08-04
KR102650756B1 (ko) 2024-03-22
AR111806A1 (es) 2019-08-21
MA49127A (fr) 2021-05-26
SG11201908660RA (en) 2019-10-30
UA124748C2 (uk) 2021-11-10

Similar Documents

Publication Publication Date Title
CL2019003257A1 (es) Derivados de indol n–sustituidos.
CL2018001325A1 (es) Derivados de indol n-sustituidos como moduladores del receptor de pge2
CL2019000169A1 (es) Derivados de piperidina.
CL2019003275A1 (es) Derivados de pirimidina como moduladores del receptor de pge2.
ECSP17074645A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
CL2020001817A1 (es) Moduladores del receptor c5a
UY36003A (es) Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina.
CO2017008156A2 (es) Derivados de 1-(4-(4-(pirimidin-5-il)tiazol-5-il)piperazin-1-il)etan-1-ona y análogos de piridina de los mismos como moduladores del receptor cxcr3, composiciones que los comprenden y métodos de elaboración
PH12015502632A1 (en) Cxcr7 receptor modulators
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
TR201904639T4 (tr) Muskarinik M1 reseptörü pozitif allosterik modülatörler.
TR201901977T4 (tr) Cxcr3 reseptörü modülatörleri olarak (r)-2-metil-piperazin türevleri.
CR20160084A (es) Derivados de amida como agonistas del receptor del ácido lisofosfatídico
TR201909997T4 (tr) 5-HT4 reseptör agonistleri olarak amid bileşikleri.
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
CL2021003348A1 (es) Derivados de piridin–3–ilo.
CO2019004143A2 (es) Compuestos azaheterocíclicos fusionados y su uso como moduladores de los receptores ampa
MX2020003832A (es) Compuestos heteroarilos como moduladores alostericos positivos del receptor muscarinico m1.
CL2017002605A1 (es) Derivados de indol
CL2023000970A1 (es) Espiro derivados de alfa-d-galactopiranosidos
UY35348A (es) Derivados de carbazol inhibidores del bromodominio y composiciones que los contienen